Xifu Liang

This inventor holds 17 USPTO granted patents and 7 published patent applications and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Leo Laboratories Limited, Leo-Pharma A/s. Active years: 2006-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xifu Liang. Retrieved from https://idiyas.com/inventor/xifu-liang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 29.4

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 32(Granted Patents)

Location History:

Frederiksberg, DK (2006)
Glostrup, DK (2011 - 2017)
Ballerup, DK (2015 - 2022)

Company Filing History:

10 out of 33

Leo Laboratories Limited

Years Active: 2006-2022

Loading Chart...

Areas of Expertise:

IL-17 Modulators

Phosphodiesterase Inhibitors

Ingenol Compounds

VEGF-2 Receptor

Aminobenzophenone

Substituted Pyrazoloazepin

Pharmaceutical Use

Chemical Synthesis

Targeted Therapy

Small Molecule Drugs

Cancer Treatment

Protein Kinase Inhibitors

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11377425 - Small molecule modulators of IL-17 (2022-07-05),

2. 11065257 - Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors (2021-07-20),

3. 10906915 - Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors (2021-02-02),

4. 10793580 - Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors (2020-10-06),

5. 9708286 - Ingenol-3-acylates III and ingenol-3-carbamates (2017-07-18),

6. 9676698 - Method of producing ingenol-3-angelate (2017-06-13),

7. 9656945 - 3-acyl-ingenols II (2017-05-23),

8. 9624157 - Process for the preparation of ingenol-3-angelate from 20-deoxy-ingenol (2017-04-18),

9. 9422309 - 3-O-heteroaryl-ingenol (2016-08-23),

10. 9416084 - Method of producing ingenol-3-angelate (2016-08-16),

11. 9404131 - Process for the preparation of ingenol-3-angelate (2016-08-02),

12. 9388124 - Ingenol-3-acylates I (2016-07-12),

13. 9102687 - Ingenol-3-acylates III and ingenol-3-carbamates (2015-08-11),

14. 8901356 - Method of producing ingenol-3-angelate (2014-12-02),

15. 8350026 - VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof (2013-01-08),

Title: Xifu Liang: Innovator in Pharmaceutical Chemistry

Introduction

Xifu Liang is a prominent inventor based in Ballerup, Denmark, known for his significant contributions to pharmaceutical chemistry. With a total of 17 patents to his name, he has made remarkable advancements in the field of medicinal compounds.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Small molecule modulators of IL-17." This invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further encompasses the use of these compounds in therapy, pharmaceutical compositions comprising said compounds, methods of treating diseases, particularly dermal diseases, and their application in the manufacture of medicaments. Another notable patent is for "Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors." This invention introduces novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, which are utilized as therapeutic agents in treating inflammatory diseases and conditions.

Career Highlights

Xifu Liang has worked with esteemed companies such as Leo Laboratories Limited and Leo Pharma A/S. His work in these organizations has significantly contributed to the development of innovative therapeutic solutions.

Collaborations

He has collaborated with notable colleagues, including Thomas Högberg and Gunnar Grue-Sørensen, enhancing the impact of his research and inventions.

Conclusion

Xifu Liang's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a leading innovator in the field. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.